Guillermo Huerta, MD
Pulmonary Disease · Omaha, NENPI 1144224841
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 28.5% of the total.
Across 262 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Intuitive Surgical$857
- Boehringer Ingelheim$464
- Johnson & Johnson$357
- GSK$333
- Insmed, Inc.$298
- plus $2K from 28 others
What the payments were for
- Travel & lodging$2504%
- Food & beverage$5,89993%
- Education$1653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,797 |
| Intuitive Surgical | 11 | $857 |
| Boehringer Ingelheim | 25 | $464 |
| Johnson & Johnson | 3 | $357 |
| GSK | 31 | $333 |
| Insmed, Inc. | 18 | $298 |
| United Therapeutics Corporation | 16 | $294 |
| Veran Medical Technologies, Inc. | 3 | $265 |
| Actelion Pharmaceuticals US, Inc. | 10 | $249 |
| Grifols USA, LLC | 12 | $221 |
| Sanofi | 12 | $201 |
| Mylan Specialty L.p. | 8 | $135 |
| Genentech USA, Inc. | 8 | $113 |
| Regeneron Healthcare Solutions, Inc. | 6 | $93 |
| Sunovion Pharmaceuticals Inc. | 14 | $88 |
| Electromed, Inc. | 6 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| Medtronic | 2 | $55 |
| Amgen | 3 | $45 |
| Philips North America LLC | 3 | $45 |
| Itamar Medical Inc | 1 | $35 |
| Verona Pharma, Inc. | 2 | $30 |
| Merck | 2 | $28 |
| Resmed Corp | 1 | $22 |
| Bayer | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Pfizer | 1 | $16 |
| Harmony Biosciences LLC | 1 | $15 |
| Hospira, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$838
- AIRSUPRA$715
- BREZTRI$715
- Da Vinci Surgical System$568
- SYMBICORT$299
- Spin$261
- MONARCH$238
- TEZSPIRE$235
- Monarch Platform$118
How this compares
$6,314 in reported general payments places this provider in the 70th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 278 | $218,098 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $59,317 |
| Breo ElliptaFluticasone/Vilanterol | 83 | $45,771 |
| Ambrisentan | 16 | $38,918 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $22,788 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $19,001 |
| Spiriva RespimatTiotropium Bromide | 34 | $17,924 |
| EliquisApixaban | 24 | $17,546 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $17,032 |
| Spiriva HandihalerTiotropium Bromide | 15 | $16,543 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $8,584 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $7,903 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $4,232 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 150 | $3,678 |
| Arnuity ElliptaFluticasone Furoate | 16 | $3,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $333 | $298,636433 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,797 | $86,221158 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $464 | $34,95559 claims |
| PfizerEliquis | $16 | $17,54624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.